Vaccine Effectiveness Against Acute Respiratory Illness Hospitalizations for Influenza-Associated Pneumonia During the 2015–2016 to 2017–2018 Seasons: US Hospitalized Adult Influenza Vaccine Effectiveness Network (HAIVEN)
Abstract Background Evidence for vaccine effectiveness (VE) against influenza-associated pneumonia has varied by season, location, and strain. We estimate VE against hospitalization for radiographically identified influenza-associated pneumonia during 2015–2016 to 2017–2018 seasons in the US Hospita...
Gespeichert in:
| Veröffentlicht in: | Clinical infectious diseases 2022-04, Vol.74 (8), p.1329-1337 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1337 |
|---|---|
| container_issue | 8 |
| container_start_page | 1329 |
| container_title | Clinical infectious diseases |
| container_volume | 74 |
| creator | Ghamande, Shekhar Shaver, Courtney Murthy, Kempapura Raiyani, Chandni White, Heath D Lat, Tasnim Arroliga, Alejandro C Wyatt, Dayna Talbot, H Keipp Martin, Emily T Monto, Arnold S Zimmerman, Richard K Middleton, Donald B Silveira, Fernanda P Ferdinands, Jill M Patel, Manish M Gaglani, Manjusha |
| description | Abstract
Background
Evidence for vaccine effectiveness (VE) against influenza-associated pneumonia has varied by season, location, and strain. We estimate VE against hospitalization for radiographically identified influenza-associated pneumonia during 2015–2016 to 2017–2018 seasons in the US Hospitalized Adult Influenza Vaccine Effectiveness Network (HAIVEN).
Methods
Among adults aged ≥18 years admitted to 10 US hospitals for acute respiratory illness (ARI), clinician-investigators used keywords from reports of chest imaging performed during 3 days around hospital admission to assign a diagnosis of “definite/probable pneumonia.” We used a test-negative design to estimate VE against hospitalization for radiographically identified laboratory-confirmed influenza-associated pneumonia, comparing reverse transcriptase–polymerase chain reaction–confirmed influenza cases with test-negative subjects. Influenza vaccination status was documented in immunization records or self-reported, including date and location. Multivariable logistic regression models were used to adjust for age, site, season, calendar-time, and other factors.
Results
Of 4843 adults hospitalized with ARI included in the primary analysis, 266 (5.5%) had “definite/probable pneumonia” and confirmed influenza. Adjusted VE against hospitalization for any radiographically confirmed influenza-associated pneumonia was 38% (95% confidence interval [CI], 17–53%); by type/subtype, it was 74% (95% CI, 52–87%) influenza A (H1N1)pdm09, 25% (95% CI, −15% to 50%) A (H3N2), and 23% (95% CI, −32% to 54%) influenza B. Adjusted VE against intensive care for any influenza was 57% (95% CI, 19–77%).
Conclusions
Influenza vaccination was modestly effective among adults in preventing hospitalizations and the need for intensive care associated with influenza pneumonia. VE was significantly higher against A (H1N1)pdm09 and was low against A (H3N2) and B.
Vaccine effectiveness against adult acute respiratory illness hospitalization for radiographically identified laboratory confirmed influenza-associated pneumonia estimated using a test-negative design was 38% (95% confidence interval: 17-53%) during 2015-2016 to 2017-2018 in the US Hospitalized Adult Influenza Vaccine Effectiveness Network (HAIVEN). |
| doi_str_mv | 10.1093/cid/ciab654 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9049268</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><oup_id>10.1093/cid/ciab654</oup_id><sourcerecordid>2556387197</sourcerecordid><originalsourceid>FETCH-LOGICAL-c412t-ac2e0cdefb9a4022cfce1c88386da63417fd5c756eadda55b924ef301179f0ea3</originalsourceid><addsrcrecordid>eNp9kt9qFDEUxgex2Fq98l5yJS0ymsxM5o8XwlDX7kKpYm1vw9nMyTaaTbZJptJe-Q4-oT6JqbvWCuJFODnJj-87HL4se8LoC0a78qXUQzowr3l1L9thvGzymnfsfrpT3uZVW7bb2cMQPlHKWEv5g2y7rMqCsobtZN_PQEptkUyUQhn1JVoMgfQL0DZE0ssxIvmAYaU9ROevyMyYX8TUpbcIRl9D1M4GopwnM6vMiPYa8j4El4aKOJD3FselsxrIm9FruyDxHEmy5z--fkulJtHdtM26bckJQkiCr8jpyR2XJNQPo4l_PMi_Rz_G-MX5z2Rv2s_OJsf7j7ItBSbg403dzU7fTj4eTPOjd4ezg_4olxUrYg6yQCoHVPMOKloUUklksk3Lqweoy4o1auCy4TXCMADn866oUJVppU2nKEK5m71e667G-RIHiTZ6MGLl9RL8lXCgxd8_Vp-LhbsUHa26om6TwN5GwLuLEUMUSx0kGgMW3RhEwXldtg3rmoQ-X6PSuxA8qlsbRsVNKEQKhdiEItFP7052y_5OQQKerQE3rv6r9BMtrsbu</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2556387197</pqid></control><display><type>article</type><title>Vaccine Effectiveness Against Acute Respiratory Illness Hospitalizations for Influenza-Associated Pneumonia During the 2015–2016 to 2017–2018 Seasons: US Hospitalized Adult Influenza Vaccine Effectiveness Network (HAIVEN)</title><source>Oxford University Press Journals All Titles (1996-Current)</source><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><creator>Ghamande, Shekhar ; Shaver, Courtney ; Murthy, Kempapura ; Raiyani, Chandni ; White, Heath D ; Lat, Tasnim ; Arroliga, Alejandro C ; Wyatt, Dayna ; Talbot, H Keipp ; Martin, Emily T ; Monto, Arnold S ; Zimmerman, Richard K ; Middleton, Donald B ; Silveira, Fernanda P ; Ferdinands, Jill M ; Patel, Manish M ; Gaglani, Manjusha</creator><creatorcontrib>Ghamande, Shekhar ; Shaver, Courtney ; Murthy, Kempapura ; Raiyani, Chandni ; White, Heath D ; Lat, Tasnim ; Arroliga, Alejandro C ; Wyatt, Dayna ; Talbot, H Keipp ; Martin, Emily T ; Monto, Arnold S ; Zimmerman, Richard K ; Middleton, Donald B ; Silveira, Fernanda P ; Ferdinands, Jill M ; Patel, Manish M ; Gaglani, Manjusha</creatorcontrib><description>Abstract
Background
Evidence for vaccine effectiveness (VE) against influenza-associated pneumonia has varied by season, location, and strain. We estimate VE against hospitalization for radiographically identified influenza-associated pneumonia during 2015–2016 to 2017–2018 seasons in the US Hospitalized Adult Influenza Vaccine Effectiveness Network (HAIVEN).
Methods
Among adults aged ≥18 years admitted to 10 US hospitals for acute respiratory illness (ARI), clinician-investigators used keywords from reports of chest imaging performed during 3 days around hospital admission to assign a diagnosis of “definite/probable pneumonia.” We used a test-negative design to estimate VE against hospitalization for radiographically identified laboratory-confirmed influenza-associated pneumonia, comparing reverse transcriptase–polymerase chain reaction–confirmed influenza cases with test-negative subjects. Influenza vaccination status was documented in immunization records or self-reported, including date and location. Multivariable logistic regression models were used to adjust for age, site, season, calendar-time, and other factors.
Results
Of 4843 adults hospitalized with ARI included in the primary analysis, 266 (5.5%) had “definite/probable pneumonia” and confirmed influenza. Adjusted VE against hospitalization for any radiographically confirmed influenza-associated pneumonia was 38% (95% confidence interval [CI], 17–53%); by type/subtype, it was 74% (95% CI, 52–87%) influenza A (H1N1)pdm09, 25% (95% CI, −15% to 50%) A (H3N2), and 23% (95% CI, −32% to 54%) influenza B. Adjusted VE against intensive care for any influenza was 57% (95% CI, 19–77%).
Conclusions
Influenza vaccination was modestly effective among adults in preventing hospitalizations and the need for intensive care associated with influenza pneumonia. VE was significantly higher against A (H1N1)pdm09 and was low against A (H3N2) and B.
Vaccine effectiveness against adult acute respiratory illness hospitalization for radiographically identified laboratory confirmed influenza-associated pneumonia estimated using a test-negative design was 38% (95% confidence interval: 17-53%) during 2015-2016 to 2017-2018 in the US Hospitalized Adult Influenza Vaccine Effectiveness Network (HAIVEN).</description><identifier>ISSN: 1058-4838</identifier><identifier>EISSN: 1537-6591</identifier><identifier>DOI: 10.1093/cid/ciab654</identifier><identifier>PMID: 34320171</identifier><language>eng</language><publisher>US: Oxford University Press</publisher><subject>Adolescent ; Adult ; Case-Control Studies ; Hospitalization ; Humans ; Influenza A Virus, H1N1 Subtype ; Influenza A Virus, H3N2 Subtype ; Influenza Vaccines ; Influenza, Human - epidemiology ; Influenza, Human - prevention & control ; Major and Commentaries ; Pneumonia - epidemiology ; Pneumonia - prevention & control ; Seasons ; Vaccination ; Vaccine Efficacy</subject><ispartof>Clinical infectious diseases, 2022-04, Vol.74 (8), p.1329-1337</ispartof><rights>The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com. 2021</rights><rights>The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c412t-ac2e0cdefb9a4022cfce1c88386da63417fd5c756eadda55b924ef301179f0ea3</citedby><cites>FETCH-LOGICAL-c412t-ac2e0cdefb9a4022cfce1c88386da63417fd5c756eadda55b924ef301179f0ea3</cites><orcidid>0000-0002-3952-9230 ; 0000-0001-6924-9494</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,776,780,881,1578,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34320171$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ghamande, Shekhar</creatorcontrib><creatorcontrib>Shaver, Courtney</creatorcontrib><creatorcontrib>Murthy, Kempapura</creatorcontrib><creatorcontrib>Raiyani, Chandni</creatorcontrib><creatorcontrib>White, Heath D</creatorcontrib><creatorcontrib>Lat, Tasnim</creatorcontrib><creatorcontrib>Arroliga, Alejandro C</creatorcontrib><creatorcontrib>Wyatt, Dayna</creatorcontrib><creatorcontrib>Talbot, H Keipp</creatorcontrib><creatorcontrib>Martin, Emily T</creatorcontrib><creatorcontrib>Monto, Arnold S</creatorcontrib><creatorcontrib>Zimmerman, Richard K</creatorcontrib><creatorcontrib>Middleton, Donald B</creatorcontrib><creatorcontrib>Silveira, Fernanda P</creatorcontrib><creatorcontrib>Ferdinands, Jill M</creatorcontrib><creatorcontrib>Patel, Manish M</creatorcontrib><creatorcontrib>Gaglani, Manjusha</creatorcontrib><title>Vaccine Effectiveness Against Acute Respiratory Illness Hospitalizations for Influenza-Associated Pneumonia During the 2015–2016 to 2017–2018 Seasons: US Hospitalized Adult Influenza Vaccine Effectiveness Network (HAIVEN)</title><title>Clinical infectious diseases</title><addtitle>Clin Infect Dis</addtitle><description>Abstract
Background
Evidence for vaccine effectiveness (VE) against influenza-associated pneumonia has varied by season, location, and strain. We estimate VE against hospitalization for radiographically identified influenza-associated pneumonia during 2015–2016 to 2017–2018 seasons in the US Hospitalized Adult Influenza Vaccine Effectiveness Network (HAIVEN).
Methods
Among adults aged ≥18 years admitted to 10 US hospitals for acute respiratory illness (ARI), clinician-investigators used keywords from reports of chest imaging performed during 3 days around hospital admission to assign a diagnosis of “definite/probable pneumonia.” We used a test-negative design to estimate VE against hospitalization for radiographically identified laboratory-confirmed influenza-associated pneumonia, comparing reverse transcriptase–polymerase chain reaction–confirmed influenza cases with test-negative subjects. Influenza vaccination status was documented in immunization records or self-reported, including date and location. Multivariable logistic regression models were used to adjust for age, site, season, calendar-time, and other factors.
Results
Of 4843 adults hospitalized with ARI included in the primary analysis, 266 (5.5%) had “definite/probable pneumonia” and confirmed influenza. Adjusted VE against hospitalization for any radiographically confirmed influenza-associated pneumonia was 38% (95% confidence interval [CI], 17–53%); by type/subtype, it was 74% (95% CI, 52–87%) influenza A (H1N1)pdm09, 25% (95% CI, −15% to 50%) A (H3N2), and 23% (95% CI, −32% to 54%) influenza B. Adjusted VE against intensive care for any influenza was 57% (95% CI, 19–77%).
Conclusions
Influenza vaccination was modestly effective among adults in preventing hospitalizations and the need for intensive care associated with influenza pneumonia. VE was significantly higher against A (H1N1)pdm09 and was low against A (H3N2) and B.
Vaccine effectiveness against adult acute respiratory illness hospitalization for radiographically identified laboratory confirmed influenza-associated pneumonia estimated using a test-negative design was 38% (95% confidence interval: 17-53%) during 2015-2016 to 2017-2018 in the US Hospitalized Adult Influenza Vaccine Effectiveness Network (HAIVEN).</description><subject>Adolescent</subject><subject>Adult</subject><subject>Case-Control Studies</subject><subject>Hospitalization</subject><subject>Humans</subject><subject>Influenza A Virus, H1N1 Subtype</subject><subject>Influenza A Virus, H3N2 Subtype</subject><subject>Influenza Vaccines</subject><subject>Influenza, Human - epidemiology</subject><subject>Influenza, Human - prevention & control</subject><subject>Major and Commentaries</subject><subject>Pneumonia - epidemiology</subject><subject>Pneumonia - prevention & control</subject><subject>Seasons</subject><subject>Vaccination</subject><subject>Vaccine Efficacy</subject><issn>1058-4838</issn><issn>1537-6591</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kt9qFDEUxgex2Fq98l5yJS0ymsxM5o8XwlDX7kKpYm1vw9nMyTaaTbZJptJe-Q4-oT6JqbvWCuJFODnJj-87HL4se8LoC0a78qXUQzowr3l1L9thvGzymnfsfrpT3uZVW7bb2cMQPlHKWEv5g2y7rMqCsobtZN_PQEptkUyUQhn1JVoMgfQL0DZE0ssxIvmAYaU9ROevyMyYX8TUpbcIRl9D1M4GopwnM6vMiPYa8j4El4aKOJD3FselsxrIm9FruyDxHEmy5z--fkulJtHdtM26bckJQkiCr8jpyR2XJNQPo4l_PMi_Rz_G-MX5z2Rv2s_OJsf7j7ItBSbg403dzU7fTj4eTPOjd4ezg_4olxUrYg6yQCoHVPMOKloUUklksk3Lqweoy4o1auCy4TXCMADn866oUJVppU2nKEK5m71e667G-RIHiTZ6MGLl9RL8lXCgxd8_Vp-LhbsUHa26om6TwN5GwLuLEUMUSx0kGgMW3RhEwXldtg3rmoQ-X6PSuxA8qlsbRsVNKEQKhdiEItFP7052y_5OQQKerQE3rv6r9BMtrsbu</recordid><startdate>20220428</startdate><enddate>20220428</enddate><creator>Ghamande, Shekhar</creator><creator>Shaver, Courtney</creator><creator>Murthy, Kempapura</creator><creator>Raiyani, Chandni</creator><creator>White, Heath D</creator><creator>Lat, Tasnim</creator><creator>Arroliga, Alejandro C</creator><creator>Wyatt, Dayna</creator><creator>Talbot, H Keipp</creator><creator>Martin, Emily T</creator><creator>Monto, Arnold S</creator><creator>Zimmerman, Richard K</creator><creator>Middleton, Donald B</creator><creator>Silveira, Fernanda P</creator><creator>Ferdinands, Jill M</creator><creator>Patel, Manish M</creator><creator>Gaglani, Manjusha</creator><general>Oxford University Press</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-3952-9230</orcidid><orcidid>https://orcid.org/0000-0001-6924-9494</orcidid></search><sort><creationdate>20220428</creationdate><title>Vaccine Effectiveness Against Acute Respiratory Illness Hospitalizations for Influenza-Associated Pneumonia During the 2015–2016 to 2017–2018 Seasons: US Hospitalized Adult Influenza Vaccine Effectiveness Network (HAIVEN)</title><author>Ghamande, Shekhar ; Shaver, Courtney ; Murthy, Kempapura ; Raiyani, Chandni ; White, Heath D ; Lat, Tasnim ; Arroliga, Alejandro C ; Wyatt, Dayna ; Talbot, H Keipp ; Martin, Emily T ; Monto, Arnold S ; Zimmerman, Richard K ; Middleton, Donald B ; Silveira, Fernanda P ; Ferdinands, Jill M ; Patel, Manish M ; Gaglani, Manjusha</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c412t-ac2e0cdefb9a4022cfce1c88386da63417fd5c756eadda55b924ef301179f0ea3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Case-Control Studies</topic><topic>Hospitalization</topic><topic>Humans</topic><topic>Influenza A Virus, H1N1 Subtype</topic><topic>Influenza A Virus, H3N2 Subtype</topic><topic>Influenza Vaccines</topic><topic>Influenza, Human - epidemiology</topic><topic>Influenza, Human - prevention & control</topic><topic>Major and Commentaries</topic><topic>Pneumonia - epidemiology</topic><topic>Pneumonia - prevention & control</topic><topic>Seasons</topic><topic>Vaccination</topic><topic>Vaccine Efficacy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ghamande, Shekhar</creatorcontrib><creatorcontrib>Shaver, Courtney</creatorcontrib><creatorcontrib>Murthy, Kempapura</creatorcontrib><creatorcontrib>Raiyani, Chandni</creatorcontrib><creatorcontrib>White, Heath D</creatorcontrib><creatorcontrib>Lat, Tasnim</creatorcontrib><creatorcontrib>Arroliga, Alejandro C</creatorcontrib><creatorcontrib>Wyatt, Dayna</creatorcontrib><creatorcontrib>Talbot, H Keipp</creatorcontrib><creatorcontrib>Martin, Emily T</creatorcontrib><creatorcontrib>Monto, Arnold S</creatorcontrib><creatorcontrib>Zimmerman, Richard K</creatorcontrib><creatorcontrib>Middleton, Donald B</creatorcontrib><creatorcontrib>Silveira, Fernanda P</creatorcontrib><creatorcontrib>Ferdinands, Jill M</creatorcontrib><creatorcontrib>Patel, Manish M</creatorcontrib><creatorcontrib>Gaglani, Manjusha</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Clinical infectious diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ghamande, Shekhar</au><au>Shaver, Courtney</au><au>Murthy, Kempapura</au><au>Raiyani, Chandni</au><au>White, Heath D</au><au>Lat, Tasnim</au><au>Arroliga, Alejandro C</au><au>Wyatt, Dayna</au><au>Talbot, H Keipp</au><au>Martin, Emily T</au><au>Monto, Arnold S</au><au>Zimmerman, Richard K</au><au>Middleton, Donald B</au><au>Silveira, Fernanda P</au><au>Ferdinands, Jill M</au><au>Patel, Manish M</au><au>Gaglani, Manjusha</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Vaccine Effectiveness Against Acute Respiratory Illness Hospitalizations for Influenza-Associated Pneumonia During the 2015–2016 to 2017–2018 Seasons: US Hospitalized Adult Influenza Vaccine Effectiveness Network (HAIVEN)</atitle><jtitle>Clinical infectious diseases</jtitle><addtitle>Clin Infect Dis</addtitle><date>2022-04-28</date><risdate>2022</risdate><volume>74</volume><issue>8</issue><spage>1329</spage><epage>1337</epage><pages>1329-1337</pages><issn>1058-4838</issn><eissn>1537-6591</eissn><abstract>Abstract
Background
Evidence for vaccine effectiveness (VE) against influenza-associated pneumonia has varied by season, location, and strain. We estimate VE against hospitalization for radiographically identified influenza-associated pneumonia during 2015–2016 to 2017–2018 seasons in the US Hospitalized Adult Influenza Vaccine Effectiveness Network (HAIVEN).
Methods
Among adults aged ≥18 years admitted to 10 US hospitals for acute respiratory illness (ARI), clinician-investigators used keywords from reports of chest imaging performed during 3 days around hospital admission to assign a diagnosis of “definite/probable pneumonia.” We used a test-negative design to estimate VE against hospitalization for radiographically identified laboratory-confirmed influenza-associated pneumonia, comparing reverse transcriptase–polymerase chain reaction–confirmed influenza cases with test-negative subjects. Influenza vaccination status was documented in immunization records or self-reported, including date and location. Multivariable logistic regression models were used to adjust for age, site, season, calendar-time, and other factors.
Results
Of 4843 adults hospitalized with ARI included in the primary analysis, 266 (5.5%) had “definite/probable pneumonia” and confirmed influenza. Adjusted VE against hospitalization for any radiographically confirmed influenza-associated pneumonia was 38% (95% confidence interval [CI], 17–53%); by type/subtype, it was 74% (95% CI, 52–87%) influenza A (H1N1)pdm09, 25% (95% CI, −15% to 50%) A (H3N2), and 23% (95% CI, −32% to 54%) influenza B. Adjusted VE against intensive care for any influenza was 57% (95% CI, 19–77%).
Conclusions
Influenza vaccination was modestly effective among adults in preventing hospitalizations and the need for intensive care associated with influenza pneumonia. VE was significantly higher against A (H1N1)pdm09 and was low against A (H3N2) and B.
Vaccine effectiveness against adult acute respiratory illness hospitalization for radiographically identified laboratory confirmed influenza-associated pneumonia estimated using a test-negative design was 38% (95% confidence interval: 17-53%) during 2015-2016 to 2017-2018 in the US Hospitalized Adult Influenza Vaccine Effectiveness Network (HAIVEN).</abstract><cop>US</cop><pub>Oxford University Press</pub><pmid>34320171</pmid><doi>10.1093/cid/ciab654</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0002-3952-9230</orcidid><orcidid>https://orcid.org/0000-0001-6924-9494</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1058-4838 |
| ispartof | Clinical infectious diseases, 2022-04, Vol.74 (8), p.1329-1337 |
| issn | 1058-4838 1537-6591 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9049268 |
| source | Oxford University Press Journals All Titles (1996-Current); MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection |
| subjects | Adolescent Adult Case-Control Studies Hospitalization Humans Influenza A Virus, H1N1 Subtype Influenza A Virus, H3N2 Subtype Influenza Vaccines Influenza, Human - epidemiology Influenza, Human - prevention & control Major and Commentaries Pneumonia - epidemiology Pneumonia - prevention & control Seasons Vaccination Vaccine Efficacy |
| title | Vaccine Effectiveness Against Acute Respiratory Illness Hospitalizations for Influenza-Associated Pneumonia During the 2015–2016 to 2017–2018 Seasons: US Hospitalized Adult Influenza Vaccine Effectiveness Network (HAIVEN) |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-05T14%3A44%3A53IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Vaccine%20Effectiveness%20Against%20Acute%20Respiratory%20Illness%20Hospitalizations%20for%20Influenza-Associated%20Pneumonia%20During%20the%202015%E2%80%932016%20to%202017%E2%80%932018%20Seasons:%20US%20Hospitalized%20Adult%20Influenza%20Vaccine%20Effectiveness%20Network%20(HAIVEN)&rft.jtitle=Clinical%20infectious%20diseases&rft.au=Ghamande,%20Shekhar&rft.date=2022-04-28&rft.volume=74&rft.issue=8&rft.spage=1329&rft.epage=1337&rft.pages=1329-1337&rft.issn=1058-4838&rft.eissn=1537-6591&rft_id=info:doi/10.1093/cid/ciab654&rft_dat=%3Cproquest_pubme%3E2556387197%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2556387197&rft_id=info:pmid/34320171&rft_oup_id=10.1093/cid/ciab654&rfr_iscdi=true |